Therefore, PARP inhibitors have the ability to prevent self-repair in BRCA1/2 mutated breast cancer cells and accelerate apoptosis of tumor cells, thereby enhancing the efficacy of chemotherapy as well as radiotherapy [82]. The gene discussed is BRCA1; the disease is breast carcinoma.